BRAS Drug Development Program

Phase l Clincial Trials Team


Exciting breakthroughs in the understanding of cancer biology continue to identify new approaches to cancer therapy. The goal of The Robert & Maggie Bras and Family New Drug Development Program at Princess Margaret Hospital is to identify new approaches to cancer therapy, for the treatment, management and eradication of this disease.


The Princess Margaret Hospital Foundation (The “Foundation”) hereby agrees to establish The Robert & Maggie Bras and Family New Drug Development Program Fund (the fund).


The purpose of the Fund would be to aid in the creation of a collaborative resource environment devoted to research in new drug development.

August 29, 2002

  • I could never have envisioned building a program quite like this,” Lillian admits. “Everybody feels such purpose. They know what they’re doing is important and they don’t want to fail anyone: patients, colleagues, or the program. They don’t want it to lose its cohesiveness, its quality. It’s definitely considered one of the top programs, not just in terms of science and research, but in terms of operational efficiency, quality and high standards. And yes, I’m saying this because it’s ours, but I think if you asked our peers, they would say the same.

    Dr. Lillian SiuDr. Lillian SiuDirector Phase l Program
  • The Bras family’s generosity and commitment to new drug development has helped pave the way to more personalized cancer treatment, which is the focus of the Princess Margaret’s Billion Dollar Challenge for Personalized Cancer Medicine.

    Greg LichtiGreg LichtiVice President Development, The Princess Margaret Cancer Foundation
  • We all know someone who has been affected by cancer, and the BRAS Drug Development Program, under the directorship of Drs. Malcolm Moore, Amit Oza, Lillian Siu, Philippe Bedard and Albiruni Razak, has achieved credibility on an international scale, and the advancements being made will bring us that much closer to finding a cure for this dreaded disease…

    Madam Hazel McCallionMadam Hazel McCallionHonorary Chair of the BRAS DDP
  • The BRAS Drug Development Program is one of the largest and most recognized drug development programs in Canada. Over the years, this remarkable program has witnessed substantial team growth and brought renewed hope to patients who have exhausted other treatment options. The lives of cancer patients have been improved, and even saved, thanks to you.

    Dr. Peter PistersDr. Peter PistersPresident and CEO of University Health Network
  • The Bras Family was remarkably visionary in establishing this center, and Canadian cancer patients are certainly indebted to the family for their generosity.

    Robert S. BellRobert S. BellMDCM, MSc, FACS, FRCSC-President and Chief Executive Officer, University Health Network (Toronto)